Drugs / Xenbilox
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT02314208 Comparator | Jan 2015 → Sep 2017 | hereditary spastic paraplegia | French National Institute of Health and Medical Research | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Xenbilox | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02314208 ↗ |
| Route | Oral | “Xenbilox (chenodeoxycholic acid) 1000mg capsule by mouth every day for 2 months” NCT02314208 ↗ |